来源: Pharmaceutical Technology
To advance its gene-modified cell therapy to clinical stages, Captain T Cell will utilise the plasmid and viral vector production expertise of Charles River. Credit: Hakat / Shutterstock.
来源: Pharmaceutical Technology
The collaboration is part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program, which provides Captain T Cell with access to contract development and manufacturing organisation (CDMO) expertise and advisory services.
The alliance is a strategic move for Captain T Cell as it prepares to manufacture a TCR-T cell therapy aimed at treating solid tumour patients in Phase I clinical trials. Captain T Cell develops treatment options for solid tumours, aiming to extend the reach of T cell immunotherapies to new patient groups. 来源: Pharmaceutical Technology
来源: Pharmaceutical Technology
The T cells seek out and eliminate tumour cells, potentially offering a new therapeutic avenue for patients whose tumours are resistant to existing treatments. To advance its gene-modified cell therapy to clinical stages, Captain T Cell will utilise the plasmid and viral vector production expertise of Charles River, which has been refined to aid CGT developers from pre-clinical through commercialisation.
Charles River has expanded its cell and gene therapy portfolio through acquisitions and facility expansions to streamline complex supply chains and cater to the increasing demand for plasmid DNA, viral vector and cell therapy services.
Charles River global manufacturing corporate senior vice-president Kerstin Dolph stated: “We are thrilled to work with the Captain T Cell team to support the manufacture of its TCR-T cell cancer immunotherapy. “Charles River has decades of success reliably manufacturing plasmid DNA, viral vectors and cell therapies, helping to safeguard our customer programmes and bring potential therapies to patients with limited options.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
来源: Pharmaceutical Technology
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy